← Back to headlines
Eli Lilly Acquires Psychedelic Drugmaker AtaiBeckley in Multi-Billion Dollar Deal
Eli Lilly has announced a deal to acquire AtaiBeckley, a psychedelic drugmaker, for up to $3.8 billion. This acquisition signals a growing interest in experimental psychedelic treatments within the pharmaceutical industry.
16 Jul, 10:48 — 16 Jul, 11:59
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (63/100)6 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center3
Center (3)
advisor-perspectivesFTbloomberg
Right2
Right (2)
seeking-alphaberlingske
Far R
Geographic diversity— 3 regions13/34
US4Denmark1UK1
Sources
Showing 4 of 6 sources
bloombergHigh16d ago
Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion - Bloomberg.com
Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion Bloomberg.com
Read full article →FTVery High16d ago
Eli Lilly buys psychedelic biotech backed by Peter Thiel
World’s biggest drugmaker agrees to buy Ataibeckley for up to $3.8bn
Read full article →cnbcMostly Factual17d ago
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
Read full article →advisor-perspectivesMostly Factual16d ago
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in the once-fringe area of psychedelic medicine.
By Eyk Henning, Madison Muller
Read full article →Coverage Timeline
First report: cnbc · 16 Jul, 10:48|Full coverage: 6 · 5h|Window: 5h
Left-leaningCenterRight-leaning
